Abstract: The present invention relates to a method for designing a cycloidal gear tooth profile of a gear shift actuator, the method designing a profile to have a backlash through a change in the radius of a rolling circle of an internal or external tooth profile of a cycloidal gear, and thus enables the smooth engagement of internal teeth and external teeth, reduces the engagement range of the internal teeth and the external teeth to have excellent durability and enable power loss to be reduced, and enables the shape machining of the gear by using general cycloidal gear machining, thereby facilitating manufacturing and being capable of improving machining precision.

Abstract: A transmitting and receiving circuit may include a first CMOS inverter configured to receive a first power supply signal and a first input signal. The transmitting and receiving circuit may include a first calculation amplifier including a non-inverted input terminal connected to an output terminal of the first CMOS inverter, and a first resistor connected between the output terminal of the first calculation amplifier and a first node. The output terminal of the first calculation amplifier and an inverted input terminal of the first calculation amplifier may be connected to each other. A first output signal may have a level smaller than that of the first input signal and may be output to the first node.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.

Abstract: Virulence factors from Burkholderia species are provided by this invention as are antibodies specifically binding the same and methods of using the virulence factors and antibodies in methods of immunizing and treating or attenuating a Burkholderia infection.

Abstract: A complementary thin film transistor (TFT) includes a substrate and a first TFT and a second TFT disposed on the substrate, wherein a first conductive semiconductor layer of the first TFT and a second gate electrode layer of the second TFT are disposed in the same layer and include the same material.

Abstract: A semiconductor package includes a substrate; a substrate pad on the substrate; a first semiconductor chip and a second semiconductor chip on the substrate; a connective terminal between the substrate pad and the first semiconductor chip and between the substrate pad and the second semiconductor chip; a dummy pad on the substrate, and spaced apart from the substrate pad, wherein the dummy pad is between the first semiconductor chip and the second semiconductor chip; and an underfill material layer interposed between the substrate and the first semiconductor chip and between the substrate and the second semiconductor chip, wherein the dummy pad and the substrate pad include a same material.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: A non-aqueous electrolyte solution for a lithium secondary battery includes a compound represented by Formula 1 as follows, a lithium salt, and an organic solvent; and a lithium secondary battery including the same: wherein R1 to R3, L1 and A? are described herein.

Abstract: The present invention relates to a pharmaceutical composition that is for treating pancreatic cancer and contains a nucleic acid complex as an active ingredient, and more specifically, to a pharmaceutical composition that is for preventing or treating pancreatic cancer and contains a nucleic acid complex in which a bioactive peptide nucleic acid, having a sequence binding to the KRAS gene, and a carrier peptide nucleic acid are complementarily bound. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity, and can effectively inhibit the expression of the KRAS gene and subtype genes thereof, and is thus useful for the prevention or treatment of pancreatic cancer.

Abstract: An assembly for a seat includes a pivot hub defining multiple rotation axes, and a displacing module attached to the pivot hub. Extendable legs are rotatably coupled to the pivot hub and comprise locking devices movable between an unlocked position, in which the legs, when extended, are enabled to retract, and a locked position, in which the legs, when extended, are prevented from retracting. The legs are rotatable between an intermediate position and a deployed position. When the legs are extended, and when in the intermediate position, the displacing module engages the locking devices to move the locking devices from the locked position to the unlocked position. When the legs are extended, rotating the legs from the intermediate position to the deployed position brings the displacing module out of contact with the locking devices.

Abstract: The present invention relates to a use of a cell adhesion molecule-related/down-regulated by oncogene (Cdo) protein or a gene encoding the same for preventing or treating neuromuscular diseases caused by damage to motor neurons, particularly muscle stem cells and neuromuscular junctions, due to aging, oxidative stress, and the like; and a method for screening for candidates for activating the expression of Cdo. When Cdo is deleted in motor neurons or neuromuscular junctions, aggravation of damage to degenerative motor neurons due to aging, and DNA damage caused by oxidative stress and inflammation are caused, which may cause neuromuscular diseases. Thus, the diseases can be treated through overexpression and activity of the Cdo protein and the gene encoding the same.

Abstract: A resin composition for preventing fibers from unraveling according to the present invention comprises ethyl acrylate; poly acrylic amide; poly urethane; methyl acrylate; formaldehyde; antistatic agent; quaternary ammonium; maleic anhydride, and surfactant.

Abstract: The present invention relates to a composition for preparing a decellularized scaffold, including nano graphene oxide. The present inventors crosslinked nano graphene oxide to a decellularized liver scaffold to strengthen the properties of the scaffold and suppress protease activity of the scaffold, and thus have established an optimum crosslinking condition exhibiting the effects of anti-inflammation and polarization to M2 macrophages. That is, since it is confirmed that nano graphene oxide strengthens the durability of the scaffold so that biodegradation is suppressed and, simultaneously, inflammatory responses that may occur after transplantation are minimized, it is expected that nano graphene oxide can be effectively used in the production and transplantation of clinically applicable artificial organs.

Abstract: Provided is a method for constructing an atopic dermatitis skin organoid from human pluripotent stem cells. It was observed that ALI-skin organoids of the presently claimed subject matter formed skin cells, appendages, neural cells, adipocytes, and the like in similar structures to those in the real skin and exhibited greatly improved follicle growth, compared to skin organoids constructed by existing culture methods. In addition, as a result of treatment with Staphylococcus aureus to construct an atopic dermatitis model, a good simulation was made of the characteristics of atopic dermatitis, such as damaged skin barriers, increased epithelium-derived cytokines and downregulated epidermal stem cell expression, causing Staphylococcus aureus colonies, and the like. Thus, the skin organoid of the presently claimed subject matter is expected to find advantageous applications as a real skin model and an atopic dermatitis model.

Abstract: A method of activating a secondary battery includes an operation of deriving a reduction reaction voltage according to an electrolyte additive, a pre-charging operation of pre-charging the secondary battery into which an electrolyte containing the electrolyte additive is injected, and a pre-aging operation of wetting an electrode assembly accommodated in the secondary battery with the injected electrolyte and aging the electrode assembly. A charging termination voltage in the pre-charging operation is less than the reduction reaction voltage.

Abstract: The present invention relates to a use for, by using the protein arginine methyltransferase 1 (PRMT1) protein or a gene encoding the same, preventing or treating a neuromuscular disease induced by motor neurons, particularly, damage to motor neurons caused by oxidative stress in the neuromuscular junction; and a method for screening a candidate material for activating the expression of PRMT1. PRMT1 deficiency in the motor nerve or neuromuscular junction induces aggravated degenerative motor nerve damage caused by aging, and DNA damage caused by oxidative stress and inflammation, thereby enabling the induction of neuromuscular disease, and thus the disease may be treated through the overexpression and activity of the PRMT1 protein and a gene encoding the same.

Abstract: The present disclosure related to a non-aqueous electrolyte solution for a lithium secondary battery, the non-aqueous electrolyte solution comprising: a lithium salt; an organic solvent; and a first additive, wherein the first additive is one or two of compounds represented by following chemical formula 1a and chemical formula 1b:

Abstract: The present invention relates to a non-aqueous electrolyte solution for a lithium secondary battery and a lithium secondary battery including the same, and particularly, to a non-aqueous electrolyte solution for a lithium secondary battery which includes a fluorine-containing compound capable of forming a stable film on the surface of an electrode as an additive, and a lithium secondary battery including the same.

Abstract: The present invention relates to an anti-inflammatory composition comprising a graphene nano-structure as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease, and a cosmetic composition or feed composition for preventing or improving an inflammatory disease, which include the anti-inflammatory composition, and a method of treating an inflammatory disease, including administering the composition to a subject in need thereof.

Abstract: The present invention relates to a method of manufacturing an animal cartilage-derived injectable composition, an injectable composition manufactured by the method, and a use thereof. The injectable composition of the present invention includes a collagen-containing biomaterial in a formulation injectable into joint cavity and may induce cartilage tissue regeneration by repairing tissue via direct injection to a target region without surgical incision. In addition, the injectable composition may be used as a therapeutic agent for arthritis by alleviating osteoarthritis not only because the animal cartilage-derived extracellular matrix contained in the injectable composition protects articular cartilage tissue but also because an environment capable of regenerating damaged articular tissue is created by inducing differentiation of intra-articular stem cells into chondrocytes.